“The Leading “Edge”
By DeeDee Deman – What defines a leading edge company in today’s tumultuous Pharma world? It’s a company that steps up to define, “Courage.” Edge Therapeutics has placed its company’s bets on changing the course of brain trauma, simultaneously redefining, “Courageous.”
Bench is honored to have brought Alyssa Wyant, now SVP Regulatory Affairs to Edge to round out their very industry-wise, best in class leadership team. Edge Therapeutics continues to prove Bench’s mantra, “The Right Leader Means Everything!”
Edge Therapeutics, Inc. (Nasdaq:EDGE), today announced the appointment of Alyssa Wyant as Senior Vice President, Regulatory Affairs. Ms. Wyant will oversee all facets of Edge’s regulatory activities, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities.